Phase II study of oral Fludarabine (FAMP) in combination with rituximab in indolent B-cell non-hodgkin lymphoma (B-NHL)

被引:0
|
作者
Ishizawa, Kenichi [1 ]
Tobinai, Kensei [2 ]
Ogura, Michinori [3 ]
Itoh, Kuniaki [4 ]
Aorishima, Yasuo [5 ]
Ando, Kiyoshi [6 ]
Yamamoto, Joji [1 ]
Watanabe, Takashi [2 ]
Uchida, Toshiki [3 ]
Nakata, Masanobu [4 ]
Hayashi, Masaki [7 ]
Hotta, Tomomitsu [8 ]
机构
[1] Tohoku Univ Hosp, Sendai, Miyagi, Japan
[2] Natl Canc Ctr, Tokyo, Japan
[3] Nagoya Daini Red Cross Hosp, Nagoya, Aichi, Japan
[4] Natl Canc Ctr Hosp, Kashiwa, Chiba, Japan
[5] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan
[6] Tokai Univ Hosp, Isehara, Kanagawa, Japan
[7] Bayer Yakuhin Ltd, Osaka, Japan
[8] Nagoya Med Ctr, Nagoya, Aichi, Japan
关键词
D O I
10.1182/blood.V110.11.1287.1287
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1287
引用
收藏
页码:387A / 387A
页数:1
相关论文
共 50 条
  • [1] Multicenter phase II study of oral fludarabine phosphate (FAMP) in relapsed indolent B-cell non-Hodgkin lymphoma (B-NHL)
    Morishima, Y
    Ogura, M
    Tobinai, K
    Minami, H
    Hayashi, M
    Hotta, T
    ANNALS OF ONCOLOGY, 2005, 16 : 155 - 155
  • [2] Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma
    Tobinai, Kensei
    Ishizawa, Ken-ichi
    Ogura, Michinori
    Itoh, Kuniaki
    Morishima, Yasuo
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Watanabe, Takashi
    Yamamoto, Joji
    Uchida, Toshiki
    Nakata, Masanobu
    Terauchi, Takashi
    Nawano, Shigeru
    Matsusako, Masaki
    Hayashi, Masaki
    Hotta, Tomomitsu
    CANCER SCIENCE, 2009, 100 (10) : 1951 - 1956
  • [3] Phase II study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma
    Tobinai, K
    Watanabe, T
    Ogura, M
    Morishima, Y
    Ogawa, Y
    Ishizawa, KI
    Minami, H
    Utsunomiya, A
    Taniwaki, M
    Terauchi, T
    Nawano, S
    Matsusako, M
    Matsuno, Y
    Nakamura, S
    Mori, S
    Ohashi, Y
    Hayashi, M
    Seriu, T
    Hotta, T
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 174 - 180
  • [4] Phase I study of bendamustine combined with rituximab in relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (B-NHL)
    Taniwaki, M.
    Ogura, M.
    Matsumoto, Y.
    Uchida, T.
    Ohmachi, K.
    Ando, K.
    Watanabe, T.
    Tobinai, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A multicenter phase II study of vorinostat in patients (pts) with relapsed or refractory indolent B-cell non-Hodgkin lymphoma (B-NHL) or mantle cell lymphoma (MCL).
    Ando, Kiyoshi
    Ogura, Michinori
    Suzuki, Tatsuya
    Ishizawa, Kenichi
    Oh, Sung Yong
    Kim, Won Seog
    Tanaka, Yoshinobu
    Shimamoto, Takashi
    Tobinai, Kensei
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] Where is the place for rituximab in the treatment of B-cell non-Hodgkin lymphoma (B-NHL) of children and adolescents?
    Patte, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 110 - 110
  • [7] Randomized phase II study of concurrent and sequential combinations of rituximab (R) plus CHOP (R-CHOP) in untreated indolent B-cell non-Hodgkin's lymphoma (B-NHL).
    Tobinai, K
    Watanabe, T
    Ogura, M
    Morishima, Y
    Itoh, K
    Igarashi, T
    Hotta, T
    Kinoshita, T
    Mori, S
    Ohashi, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 576S - 576S
  • [8] Phase I and pharmacokinetic study of oral fludarabine phosphate in relapsed indolent B-cell non-Hodgkin's lymphoma
    Ogawa, Y
    Hotta, T
    Tobinai, K
    Watanabe, T
    Sasaki, Y
    Minami, H
    Morishima, Y
    Ogura, M
    Seriu, T
    ANNALS OF ONCOLOGY, 2006, 17 (02) : 330 - 333
  • [9] A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma
    Torka, Pallawi
    Patel, Priyank
    Tan, Wei
    Wilding, Gregory
    Bhat, Seema A.
    Czuczman, Myron S.
    Lee, Kelvin P.
    Deeb, George
    Neppalli, Vishala
    Mavis, Cory
    Wallace, Paul
    Hernandez-Ilizaliturri, Francisco J.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (01): : E51 - E60
  • [10] A phase II, multicenter study of bendamustine HCl plus rituximab in relapsed indolent B-cell and mantle-cell non-Hodgkin's lymphoma (NHL).
    Williams, M. E.
    Cohen, P.
    Tulpule, A.
    Van der Jagt, R. H.
    Herst, J. A.
    Bessudo, A.
    Lemieux, B.
    Schwartzberg, L. S.
    Oliver, J. W.
    Robinson, K. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 429S - 429S